Prostate cancer is the second most common cancer in men and the fifth leading cause of death from cancer in men worldwide, according to 2012 numbers. While several viable treatment options for prostate cancer exist, many men affected with prostate cancer will not respond to first-line treatments. Researchers have now developed a new technology for liquid biopsy to identify which patients may not respond to standard therapy before it is delivered.